Re: [CJRT] Article Review Request

Dari: desdiani - (desdiani@ymail.com)

Kepada: editor@csrt.com

Tanggal: Jumat, 30 September 2022 pukul 08.11 GMT+7

Okay Carly, i agree to review this manuscript

> Pada Jumat, 30 September 2022 03.13.28 GMT+7, Carly Brockington <editor@csrt.com> menulis:
>
> Desdiani Desdiani:
>
> I believe that you would serve as an excellent reviewer of the manuscript, "Antifibrotic Effect of Ciplukan (Physalis angulata Linn.) Against Bleomycin-Induced Pulmonary Fibrosis in Mice via Alveolar Regeneration and Anti-Inflammatory," which has been submitted to Canadian Journal of Respiratory Therapy. The submission's abstract is inserted below, and I hope that you will consider undertaking this important task for us.
>
> Please log into the journal web site by 2022-10-06 to indicate whether you will undertake the review or not, as well as to access the submission and to record your review and recommendation.
>
> The review itself is due 2022-10-20.
>
> Submission URL: https://cjrtmanuscript.com/index.php/CJRT/reviewer/submission?submissionId=227&reviewId=334&key=dEifC9
>
> Thank you for considering this request.
>
> Carly Brockington
> editor@csrt.com
>
> "Antifibrotic Effect of Ciplukan (Physalis angulata Linn.) Against Bleomycin-Induced Pulmonary Fibrosis in Mice via Alveolar Regeneration and Anti-Inflammatory"
>
> **Background:** Herbal medicine began to be developed as an antifibrosis drug for pulmonary fibrosis. Ciplukan (*Physalis angulata* Linn.) is a wild plant that has been widely used for generations as traditional Indonesian medicine for various diseases; but has never been studied as an antifibrosis. This study aimed to determine Ciplukan herb ethanol extract (CPL) bioactivity as antifibrosis in pulmonary fibrosis disorders in experimental mice model induced by bleomycin.
>
> **Methods:** A total of 35 male mice and 35 female mice of the ddy strain was divided into 7 groups. For the pulmonary fibrosis model, bleomycin (BLM) was injected subcutaneously 8 times with a frequency of twice a week for 4 weeks. Furthermore, the mice were given CPL orally starting at week 6 of treatment with 2 different doses, 0.16 mg (CPL-1) and 0.32 mg (CPL) every day for 4 weeks. Pulmonary fibrosis histopathology was analyzed using HE and MT staining methods. Serum IL-6, KL-6, and TGF-β1 levels determination was carried out using the ELISA method.
>
> **Result:** The administration of CPL significantly reduced the fibrosis score from 2.80±1.095 to 1.67±0.577 μm (p=0.026). The CPL also showed anti-inflammatory activity by reducing IL-6 levels from 1916.20±594.27 to 16.81±17.07 pg/mL (p=0.003); TGF-β1 levels from 51.25±2.25 to 22.48±0.93 ng/mL (p=0.021); and KL-6 levels from 28.09±2.25 to 13.99±0.93 ng/mL (p=0.000).
>
> **Conclusion:** CPL was proven to have pulmonary antifibrotic activity in experimental mice model. The pulmonary antifibrotic effect was evidenced by a decrease in pulmonary fibrosis scores also a decrease in KL-6 levels, IL-6 levels, and TGF-β1.

Carly Brockington

Managing Editor

editor@csrt.com

Canadian Journal of Respiratory Therapy

RE: [CJRT] Article Review Request

Dari: Editor (editor@csrt.com)

Kepada: desdiani@ymail.com

Tanggal: Selasa, 4 Oktober 2022 pukul 22.21 GMT+7

Thank you! I accepted the review invite on your behalf in the system, your comments are due Oct 20th. If you prefer, you can send a list of numbered comments directly to me (or insert comments into the Word document), and I can load your feedback into the system.

Thanks again!

Carly Brockington
Managing Editor, Canadian Journal of Respiratory Therapy
(Pronouns: she, her)
201-2460 Lancaster Road Ottawa, ON K1B 4S5
Tel : (613) 808-8833

From: desdiani - <desdiani@ymail.com>
Sent: September 29, 2022 9:12 PM
To: Editor <editor@csrt.com>
Subject: Re: [CJRT] Article Review Request

Okay Carly, i agree to review this manuscript

Pada Jumat, 30 September 2022 03.13.28 GMT+7, Carly Brockington <editor@csrt.com> menulis:

Desdiani Desdiani:

I believe that you would serve as an excellent reviewer of the manuscript, "Antifibrotic Effect of Ciplukan (Physalis angulata Linn.) Against Bleomycin-Induced Pulmonary Fibrosis in Mice via Alveolar Regeneration and Anti-Inflammatory," which has been submitted to Canadian Journal of Respiratory Therapy. The submission's abstract is inserted below, and I hope that you will consider undertaking this important task for us.

Please log into the journal web site by 2022-10-06 to indicate whether you will undertake the review or not, as well as to access the submission and to record your review and recommendation.

The review itself is due 2022-10-20.

Submission URL: https://cjrtmanuscript.com/index.php/CJRT/reviewer/submission?submissionId=227&reviewId=334&key=dEifC9

Thank you for considering this request.

Carly Brockington
editor@csrt.com

"Antifibrotic Effect of Ciplukan (Physalis angulata Linn.) Against Bleomycin-Induced Pulmonary Fibrosis in Mice via Alveolar Regeneration and Anti-Inflammatory"

Background: Herbal medicine began to be developed as an antifibrosis drug for pulmonary fibrosis. Ciplukan (*Physalis angulata* Linn.) is a wild plant that has been widely used for generations as traditional Indonesian medicine for various diseases; but has never been studied as an antifibrosis. This study aimed to determine Ciplukan herb ethanol extract (CPL) bioactivity as antifibrosis in pulmonary fibrosis disorders in experimental mice model induced by bleomycin.

Methods: A total of 35 male mice and 35 female mice of the ddy strain was divided into 7 groups. For the pulmonary fibrosis model, bleomycin (BLM) was injected subcutaneously 8 times with a frequency of twice a week for 4 weeks. Furthermore, the mice were given CPL orally starting at week 6 of treatment with 2 different doses, 0.16 mg (CPL-1) and 0.32 mg (CPL) every day for 4 weeks. Pulmonary fibrosis histopathology was analyzed using HE and MT staining methods. Serum IL-6, KL-6, and TGF-β1 levels determination was carried out using the ELISA method.

Result: The administration of CPL significantly reduced the fibrosis score from 2.80±1.095 to 1.67±0.577 μm (p=0.026). The CPL also showed anti-inflammatory activity by reducing IL-6 levels from 1916.20±594.27 to 16.81±17.07 pg/mL (p=0.003); TGF-β1 levels from 51.25±2.25 to 22.48±0.93 ng/mL (p=0.021); and KL-6 levels from 28.09±2.25 to 13.99±0.93 ng/mL (p=0.000).

Conclusion: CPL was proven to have pulmonary antifibrotic activity in experimental mice model. The pulmonary antifibrotic effect was evidenced by a decrease in pulmonary fibrosis scores also a decrease in KL-6 levels, IL-6 levels, and TGF-β1.

Carly Brockington

Managing Editor

editor@csrt.com

Canadian Journal of Respiratory Therapy

CJRT 2022-55 for review.docx
1023.7kB

Re: [CJRT] Submission Review Reminder

Dari: desdiani - (desdiani@ymail.com)

Kepada: editor@csrt.com

Tanggal: Jumat, 25 November 2022 pukul 22.36 GMT+7

Okay Carly. Thanks

> Pada Rabu, 16 November 2022 06.42.17 GMT+7, Carly Brockington <editor@csrt.com> menulis:
>
> Desdiani Desdiani:
>
> Just a gentle reminder of our request for your review of the submission, "Antifibrotic Effect of Ciplukan (Physalis angulata Linn.) Against Bleomycin-Induced Pulmonary Fibrosis in Mice via Alveolar Regeneration and Anti-Inflammatory," for Canadian Journal of Respiratory Therapy. We were hoping to have this review by 2022-10-20, and would be pleased to receive it as soon as you are able to prepare it.
>
> Submission URL: https://cjrtmanuscript.com/index.php/CJRT/reviewer/submission?submissionId=227&reviewId=334&key=2CkvPf
>
> Please confirm your ability to complete this vital contribution to the work of the journal. I look forward to hearing from you.
>
> Carly Brockington
> editor@csrt.com
>
> **Carly Brockington**
>
> Managing Editor
>
> editor@csrt.com
>
> _____
> Canadian Journal of Respiratory Therapy

RE: [CJRT] Article Review due

Dari: Editor (editor@csrt.com)

Kepada: desdiani@ymail.com

Tanggal: Selasa, 6 Desember 2022 pukul 03.43 GMT+7

Thank you for such thorough and constructive feedback; this is wonderful! We appreciate your contribution to the quality of the work that we publish.
If you would like to receive an official letter awarding 2 education hours that can be applied to a CPD program, please let me know. You may also request a letter that can be addressed to your employer, recognizing your contribution as a peer reviewer for the CJRT.
Kind regards,
Carly Brockington
Managing Editor, Canadian Journal of Respiratory Therapy
(Pronouns: she, her)
201-2460 Lancaster Road Ottawa, ON K1B 4S5
Tel : (613) 808-8833

From: desdiani - <desdiani@ymail.com>
Sent: December 5, 2022 1:19 AM
To: Editor <editor@csrt.com>
Subject: Re: [CJRT] Article Review due

Dear Carly,

I've submitted a manuscript review.

Thank you

Best Regards,

Desdiani Desdiani

Pada Rabu, 16 November 2022 06.44.53 GMT+7, Editor <editor@csrt.com> menulis:

Hello, I am just following up on this review – can you send me your comments in the next few days?

Kind regards,

Carly Brockington
Managing Editor, Canadian Journal of Respiratory Therapy
(Pronouns: she, her)
201-2460 Lancaster Road Ottawa, ON K1B 4S5
Tel : (613) 808-8833

From: Editor
Sent: October 4, 2022 11:22 AM
To: desdiani - <desdiani@ymail.com>
Subject: RE: [CJRT] Article Review Request

Thank you! I accepted the review invite on your behalf in the system, your comments are due Oct 20th. If you prefer, you can send a list of numbered comments directly to me (or insert comments into the Word document), and I can load your feedback into the system.

Thanks again!

Carly Brockington
Managing Editor, Canadian Journal of Respiratory Therapy
(Pronouns: she, her)
201-2460 Lancaster Road Ottawa, ON K1B 4S5
Tel : (613) 808-8833

From: desdiani - <desdiani@ymail.com>
Sent: September 29, 2022 9:12 PM
To: Editor <editor@csrt.com>
Subject: Re: [CJRT] Article Review Request

Okay Carly, i agree to review this manuscript

Pada Jumat, 30 September 2022 03.13.28 GMT+7, Carly Brockington <editor@csrt.com> menulis:

Desdiani Desdiani:

I believe that you would serve as an excellent reviewer of the manuscript, "Antifibrotic Effect of Ciplukan (Physalis angulata Linn.) Against Bleomycin-Induced Pulmonary Fibrosis in Mice via Alveolar Regeneration and Anti-Inflammatory," which has been submitted to Canadian Journal of Respiratory Therapy. The submission's abstract is inserted below, and I hope that you will consider undertaking this important task for us.

Please log into the journal web site by 2022-10-06 to indicate whether you will undertake the review or not, as well as to access the submission and to record your review and recommendation.

The review itself is due 2022-10-20.

Submission URL: https://cjrtmanuscript.com/index.php/CJRT/reviewer/submission?submissionId=227&reviewId=334&key=dEifC9

Thank you for considering this request.

Carly Brockington
editor@csrt.com

"Antifibrotic Effect of Ciplukan (Physalis angulata Linn.) Against Bleomycin-Induced Pulmonary Fibrosis in Mice via Alveolar Regeneration and Anti-Inflammatory"

Background: Herbal medicine began to be developed as an antifibrosis drug for pulmonary fibrosis. Ciplukan (*Physalis angulata* Linn.) is a wild plant that has been widely used for generations as traditional Indonesian medicine for various diseases; but has never been studied as an antifibrosis. This study aimed to determine Ciplukan herb ethanol extract (CPL) bioactivity as antifibrosis in pulmonary fibrosis disorders in experimental mice model induced by bleomycin.

Methods: A total of 35 male mice and 35 female mice of the ddy strain was divided into 7 groups. For the pulmonary fibrosis model, bleomycin (BLM) was injected subcutaneously 8 times with a frequency of twice a week for 4 weeks. Furthermore, the mice were given CPL orally starting at week 6 of treatment with 2 different doses, 0.16 mg (CPL-1) and 0.32 mg (CPL) every day for 4 weeks. Pulmonary fibrosis histopathology was analyzed using HE and MT staining methods. Serum IL-6, KL-6, and TGF-β1 levels determination was carried out using the ELISA method.

Result: The administration of CPL significantly reduced the fibrosis score from 2.80±1.095 to 1.67±0.577 μm (p=0.026). The CPL also showed anti-inflammatory activity by reducing IL-6 levels from 1916.20±594.27 to 16.81±17.07 pg/mL (p=0.003); TGF-β1 levels from 51.25±2.25 to 22.48±0.93 ng/mL (p=0.021); and KL-6 levels from 28.09±2.25 to 13.99±0.93 ng/mL (p=0.000).

Conclusion: CPL was proven to have pulmonary antifibrotic activity in experimental mice model. The pulmonary antifibrotic effect was evidenced by a decrease in pulmonary fibrosis scores also a decrease in KL-6 levels, IL-6 levels, and TGF-β1.

Carly Brockington

Managing Editor

editor@csrt.com

_____

Canadian Journal of Respiratory Therapy

Re: [CJRT] New notification from Canadian Journal of Respiratory Therapy

Dari: desdiani - (desdiani@ymail.com)

Kepada: editor@csrt.com

Tanggal: Minggu, 30 April 2023 pukul 23.15 GMT+7

Dear Carly,
I hope you well.
I am sorry for late respons, because i have some urgent tasks to be completed lately, and thankfully all have been done
I"ve sent the review.
Thanks for your attention.

Best Regards,
Desdiani

> Pada Rabu, 12 April 2023 pukul 21.31.23 GMT+7, Carly Brockington <editor@csrt.com> menulis:
>
> You have a new notification from Canadian Journal of Respiratory Therapy:
>
> Review assignment updated.
>
> Link: https://cjrtmanuscript.com/index.php/CJRT/reviewer/submission/227
>
> Carly Brockington
>
> **Carly Brockington**
>
> Managing Editor
>
> editor@csrt.com
>
> _____
>
> Canadian Journal of Respiratory Therapy

CANADIAN JOURNAL OF RESPIRATORY THERAPY
CJRT · JCTR
JOURNAL CANADIEN DE THÉRAPIE RESPIRATOIRE
Informing the Practice of Respiratory Therapists Globally

January 15, 2023

Desdiani
Faculty of Medicine, Universitas Sultan Ageng Tirtayasa
Serang, Banten
Indonesia

Dear Desdiani,

This confirms your contribution to the *Canadian Journal of Respiratory Therapy* as a volunteer peer reviewer for submissions CJRT-2022-55. Your feedback has helped to maintain and enhance the clinical relevance and scientific quality of articles published in the *Journal* – thank you!

Your contributions have earned 2 credits, which can be put towards any Canadian continuing education requirements. One credit equals one hour of continuing professional development (CPD) / continuing education (CE) that will be recognized by Canadian Society of Respiratory Therapy's (CSRT) provincial organizations and/or other regulatory bodies for CPD/CE requirements.

Sincerely,

Carly Brockington
Managing Editor, CJRT